The Valley Desk

NCT01968551 · Interventional trial

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Overall registry status Completed

Phase 3

Conditions Acquired Immunodeficiency Syndrome, HIV Infections, HIV-1

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov